RecruitingNot ApplicableNCT07704424

Safety and Feasibility of the CorVad Percutaneous Ventricular Assist System in Refractory Right Heart Failure

Sponsor

Shenzhen Core Medical Technology CO.,LTD.

Enrollment

6 participants

Start Date

Jun 2, 2026

Study Type

INTERVENTIONAL

Conditions

Right Heart Failure

Summary

The goal of this clinical trial is to evaluate the safety and feasibility of the CorVad Percutaneous Ventricular Assist System (Device model: CorVad RS) in patients with right heart failure who continue to experience hemodynamic instability despite best medical therapy.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a medical device called CorVad Percutaneous Ventricular Assist System for people with right heart failure. The study is currently recruiting participants at 2 locations. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DEVICECorVad Percutaneous Ventricular Assist System

The CorVad Percutaneous Ventricular Assist System (Device model: CorVad RS) is used to provide hemodynamic support by shareing some or all the workload of the right ventricles during the support period.